Deep Learning for Automated Contouring of Primary Tumor Volumes by MRI for Nasopharyngeal Carcinoma

Background Nasopharyngeal carcinoma (NPC) may be cured with radiation therapy. Tumor proximity to critical structures demands accuracy in tumor delineation to avoid toxicities from radiation therapy; however, tumor target contouring for head and neck radiation therapy is labor intensive and highly v...

Full description

Saved in:
Bibliographic Details
Published in:Radiology Vol. 291; no. 3; p. 677
Main Authors: Lin, Li, Dou, Qi, Jin, Yue-Ming, Zhou, Guan-Qun, Tang, Yi-Qiang, Chen, Wei-Lin, Su, Bao-An, Liu, Feng, Tao, Chang-Juan, Jiang, Ning, Li, Jun-Yun, Tang, Ling-Long, Xie, Chuan-Miao, Huang, Shao-Min, Ma, Jun, Heng, Pheng-Ann, Wee, Joseph T S, Chua, Melvin L K, Chen, Hao, Sun, Ying
Format: Journal Article
Language:English
Published: United States 01.06.2019
Subjects:
ISSN:1527-1315, 1527-1315
Online Access:Get more information
Tags: Add Tag
No Tags, Be the first to tag this record!
Abstract Background Nasopharyngeal carcinoma (NPC) may be cured with radiation therapy. Tumor proximity to critical structures demands accuracy in tumor delineation to avoid toxicities from radiation therapy; however, tumor target contouring for head and neck radiation therapy is labor intensive and highly variable among radiation oncologists. Purpose To construct and validate an artificial intelligence (AI) contouring tool to automate primary gross tumor volume (GTV) contouring in patients with NPC. Materials and Methods In this retrospective study, MRI data sets covering the nasopharynx from 1021 patients (median age, 47 years; 751 male, 270 female) with NPC between September 2016 and September 2017 were collected and divided into training, validation, and testing cohorts of 715, 103, and 203 patients, respectively. GTV contours were delineated for 1021 patients and were defined by consensus of two experts. A three-dimensional convolutional neural network was applied to 818 training and validation MRI data sets to construct the AI tool, which was tested in 203 independent MRI data sets. Next, the AI tool was compared against eight qualified radiation oncologists in a multicenter evaluation by using a random sample of 20 test MRI examinations. The Wilcoxon matched-pairs signed rank test was used to compare the difference of Dice similarity coefficient (DSC) of pre- versus post-AI assistance. Results The AI-generated contours demonstrated a high level of accuracy when compared with ground truth contours at testing in 203 patients (DSC, 0.79; 2.0-mm difference in average surface distance). In multicenter evaluation, AI assistance improved contouring accuracy (five of eight oncologists had a higher median DSC after AI assistance; average median DSC, 0.74 vs 0.78; < .001), reduced intra- and interobserver variation (by 36.4% and 54.5%, respectively), and reduced contouring time (by 39.4%). Conclusion The AI contouring tool improved primary gross tumor contouring accuracy of nasopharyngeal carcinoma, which could have a positive impact on tumor control and patient survival. © RSNA, 2019 See also the editorial by Chang in this issue.
AbstractList Background Nasopharyngeal carcinoma (NPC) may be cured with radiation therapy. Tumor proximity to critical structures demands accuracy in tumor delineation to avoid toxicities from radiation therapy; however, tumor target contouring for head and neck radiation therapy is labor intensive and highly variable among radiation oncologists. Purpose To construct and validate an artificial intelligence (AI) contouring tool to automate primary gross tumor volume (GTV) contouring in patients with NPC. Materials and Methods In this retrospective study, MRI data sets covering the nasopharynx from 1021 patients (median age, 47 years; 751 male, 270 female) with NPC between September 2016 and September 2017 were collected and divided into training, validation, and testing cohorts of 715, 103, and 203 patients, respectively. GTV contours were delineated for 1021 patients and were defined by consensus of two experts. A three-dimensional convolutional neural network was applied to 818 training and validation MRI data sets to construct the AI tool, which was tested in 203 independent MRI data sets. Next, the AI tool was compared against eight qualified radiation oncologists in a multicenter evaluation by using a random sample of 20 test MRI examinations. The Wilcoxon matched-pairs signed rank test was used to compare the difference of Dice similarity coefficient (DSC) of pre- versus post-AI assistance. Results The AI-generated contours demonstrated a high level of accuracy when compared with ground truth contours at testing in 203 patients (DSC, 0.79; 2.0-mm difference in average surface distance). In multicenter evaluation, AI assistance improved contouring accuracy (five of eight oncologists had a higher median DSC after AI assistance; average median DSC, 0.74 vs 0.78; < .001), reduced intra- and interobserver variation (by 36.4% and 54.5%, respectively), and reduced contouring time (by 39.4%). Conclusion The AI contouring tool improved primary gross tumor contouring accuracy of nasopharyngeal carcinoma, which could have a positive impact on tumor control and patient survival. © RSNA, 2019 See also the editorial by Chang in this issue.
Background Nasopharyngeal carcinoma (NPC) may be cured with radiation therapy. Tumor proximity to critical structures demands accuracy in tumor delineation to avoid toxicities from radiation therapy; however, tumor target contouring for head and neck radiation therapy is labor intensive and highly variable among radiation oncologists. Purpose To construct and validate an artificial intelligence (AI) contouring tool to automate primary gross tumor volume (GTV) contouring in patients with NPC. Materials and Methods In this retrospective study, MRI data sets covering the nasopharynx from 1021 patients (median age, 47 years; 751 male, 270 female) with NPC between September 2016 and September 2017 were collected and divided into training, validation, and testing cohorts of 715, 103, and 203 patients, respectively. GTV contours were delineated for 1021 patients and were defined by consensus of two experts. A three-dimensional convolutional neural network was applied to 818 training and validation MRI data sets to construct the AI tool, which was tested in 203 independent MRI data sets. Next, the AI tool was compared against eight qualified radiation oncologists in a multicenter evaluation by using a random sample of 20 test MRI examinations. The Wilcoxon matched-pairs signed rank test was used to compare the difference of Dice similarity coefficient (DSC) of pre- versus post-AI assistance. Results The AI-generated contours demonstrated a high level of accuracy when compared with ground truth contours at testing in 203 patients (DSC, 0.79; 2.0-mm difference in average surface distance). In multicenter evaluation, AI assistance improved contouring accuracy (five of eight oncologists had a higher median DSC after AI assistance; average median DSC, 0.74 vs 0.78; P < .001), reduced intra- and interobserver variation (by 36.4% and 54.5%, respectively), and reduced contouring time (by 39.4%). Conclusion The AI contouring tool improved primary gross tumor contouring accuracy of nasopharyngeal carcinoma, which could have a positive impact on tumor control and patient survival. © RSNA, 2019 Online supplemental material is available for this article. See also the editorial by Chang in this issue.Background Nasopharyngeal carcinoma (NPC) may be cured with radiation therapy. Tumor proximity to critical structures demands accuracy in tumor delineation to avoid toxicities from radiation therapy; however, tumor target contouring for head and neck radiation therapy is labor intensive and highly variable among radiation oncologists. Purpose To construct and validate an artificial intelligence (AI) contouring tool to automate primary gross tumor volume (GTV) contouring in patients with NPC. Materials and Methods In this retrospective study, MRI data sets covering the nasopharynx from 1021 patients (median age, 47 years; 751 male, 270 female) with NPC between September 2016 and September 2017 were collected and divided into training, validation, and testing cohorts of 715, 103, and 203 patients, respectively. GTV contours were delineated for 1021 patients and were defined by consensus of two experts. A three-dimensional convolutional neural network was applied to 818 training and validation MRI data sets to construct the AI tool, which was tested in 203 independent MRI data sets. Next, the AI tool was compared against eight qualified radiation oncologists in a multicenter evaluation by using a random sample of 20 test MRI examinations. The Wilcoxon matched-pairs signed rank test was used to compare the difference of Dice similarity coefficient (DSC) of pre- versus post-AI assistance. Results The AI-generated contours demonstrated a high level of accuracy when compared with ground truth contours at testing in 203 patients (DSC, 0.79; 2.0-mm difference in average surface distance). In multicenter evaluation, AI assistance improved contouring accuracy (five of eight oncologists had a higher median DSC after AI assistance; average median DSC, 0.74 vs 0.78; P < .001), reduced intra- and interobserver variation (by 36.4% and 54.5%, respectively), and reduced contouring time (by 39.4%). Conclusion The AI contouring tool improved primary gross tumor contouring accuracy of nasopharyngeal carcinoma, which could have a positive impact on tumor control and patient survival. © RSNA, 2019 Online supplemental material is available for this article. See also the editorial by Chang in this issue.
Author Dou, Qi
Sun, Ying
Chen, Wei-Lin
Zhou, Guan-Qun
Tang, Yi-Qiang
Huang, Shao-Min
Jiang, Ning
Lin, Li
Wee, Joseph T S
Heng, Pheng-Ann
Li, Jun-Yun
Chua, Melvin L K
Jin, Yue-Ming
Xie, Chuan-Miao
Liu, Feng
Tao, Chang-Juan
Ma, Jun
Su, Bao-An
Chen, Hao
Tang, Ling-Long
Author_xml – sequence: 1
  givenname: Li
  orcidid: 0000-0003-1052-1566
  surname: Lin
  fullname: Lin, Li
  organization: From the Department of Radiation Oncology (L.L., G.Q.Z., J.Y.L., L.L.T., S.M.H., J.M., Y.S.) and Imaging Diagnosis and Interventional Center (C.M.X.), Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, 651 Dongfeng Rd East, Guangzhou 510060, China; Department of Computer Science and Engineering, The Chinese University of Hong Kong, Hong Kong SAR (Q.D., Y.M.J., P.A.H., H.C.); Imsight Medical Technology, Shenzhen, China (H.C.); Divisions of Radiation Oncology (J.T.S.W., M.L.K.C.) and Medical Sciences (M.L.K.C.), National Cancer Center Singapore, Singapore; Oncology Academic Programme, Duke-NUS Medical School, Singapore (M.L.K.C.); Department of Radiation Oncology, Jiangxi Cancer Hospital, Nanchang, China (Y.Q.T.); Department of Radiation Oncology, Zhangzhou Affiliated Hospital of Fujian Medical University, Zhangzhou, China (W.L.C.); Department of Radiation Oncology, Quanzhou First Hospital Affiliated to Fujian Medical University, Quanzhou, China (B.A.S.); Department of Radiation Oncology, The First Affiliated Hospital of Fujian Medical University, Fuzhou, China (F.L.); Department of Radiation Oncology, Zhejiang Provincial Cancer Hospital, Key Laboratory of Radiation Oncology of Zhejiang Province, Hangzhou, China (C.J.T.); and Department of Radiation Oncology, Nanjing Medical University Affiliated Cancer Hospital, Jiangsu Cancer Hospital and Jiangsu Institute of Cancer Research, Nanjing, China (N.J.)
– sequence: 2
  givenname: Qi
  orcidid: 0000-0002-3416-9950
  surname: Dou
  fullname: Dou, Qi
  organization: From the Department of Radiation Oncology (L.L., G.Q.Z., J.Y.L., L.L.T., S.M.H., J.M., Y.S.) and Imaging Diagnosis and Interventional Center (C.M.X.), Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, 651 Dongfeng Rd East, Guangzhou 510060, China; Department of Computer Science and Engineering, The Chinese University of Hong Kong, Hong Kong SAR (Q.D., Y.M.J., P.A.H., H.C.); Imsight Medical Technology, Shenzhen, China (H.C.); Divisions of Radiation Oncology (J.T.S.W., M.L.K.C.) and Medical Sciences (M.L.K.C.), National Cancer Center Singapore, Singapore; Oncology Academic Programme, Duke-NUS Medical School, Singapore (M.L.K.C.); Department of Radiation Oncology, Jiangxi Cancer Hospital, Nanchang, China (Y.Q.T.); Department of Radiation Oncology, Zhangzhou Affiliated Hospital of Fujian Medical University, Zhangzhou, China (W.L.C.); Department of Radiation Oncology, Quanzhou First Hospital Affiliated to Fujian Medical University, Quanzhou, China (B.A.S.); Department of Radiation Oncology, The First Affiliated Hospital of Fujian Medical University, Fuzhou, China (F.L.); Department of Radiation Oncology, Zhejiang Provincial Cancer Hospital, Key Laboratory of Radiation Oncology of Zhejiang Province, Hangzhou, China (C.J.T.); and Department of Radiation Oncology, Nanjing Medical University Affiliated Cancer Hospital, Jiangsu Cancer Hospital and Jiangsu Institute of Cancer Research, Nanjing, China (N.J.)
– sequence: 3
  givenname: Yue-Ming
  orcidid: 0000-0003-3775-3877
  surname: Jin
  fullname: Jin, Yue-Ming
  organization: From the Department of Radiation Oncology (L.L., G.Q.Z., J.Y.L., L.L.T., S.M.H., J.M., Y.S.) and Imaging Diagnosis and Interventional Center (C.M.X.), Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, 651 Dongfeng Rd East, Guangzhou 510060, China; Department of Computer Science and Engineering, The Chinese University of Hong Kong, Hong Kong SAR (Q.D., Y.M.J., P.A.H., H.C.); Imsight Medical Technology, Shenzhen, China (H.C.); Divisions of Radiation Oncology (J.T.S.W., M.L.K.C.) and Medical Sciences (M.L.K.C.), National Cancer Center Singapore, Singapore; Oncology Academic Programme, Duke-NUS Medical School, Singapore (M.L.K.C.); Department of Radiation Oncology, Jiangxi Cancer Hospital, Nanchang, China (Y.Q.T.); Department of Radiation Oncology, Zhangzhou Affiliated Hospital of Fujian Medical University, Zhangzhou, China (W.L.C.); Department of Radiation Oncology, Quanzhou First Hospital Affiliated to Fujian Medical University, Quanzhou, China (B.A.S.); Department of Radiation Oncology, The First Affiliated Hospital of Fujian Medical University, Fuzhou, China (F.L.); Department of Radiation Oncology, Zhejiang Provincial Cancer Hospital, Key Laboratory of Radiation Oncology of Zhejiang Province, Hangzhou, China (C.J.T.); and Department of Radiation Oncology, Nanjing Medical University Affiliated Cancer Hospital, Jiangsu Cancer Hospital and Jiangsu Institute of Cancer Research, Nanjing, China (N.J.)
– sequence: 4
  givenname: Guan-Qun
  orcidid: 0000-0002-7989-4224
  surname: Zhou
  fullname: Zhou, Guan-Qun
  organization: From the Department of Radiation Oncology (L.L., G.Q.Z., J.Y.L., L.L.T., S.M.H., J.M., Y.S.) and Imaging Diagnosis and Interventional Center (C.M.X.), Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, 651 Dongfeng Rd East, Guangzhou 510060, China; Department of Computer Science and Engineering, The Chinese University of Hong Kong, Hong Kong SAR (Q.D., Y.M.J., P.A.H., H.C.); Imsight Medical Technology, Shenzhen, China (H.C.); Divisions of Radiation Oncology (J.T.S.W., M.L.K.C.) and Medical Sciences (M.L.K.C.), National Cancer Center Singapore, Singapore; Oncology Academic Programme, Duke-NUS Medical School, Singapore (M.L.K.C.); Department of Radiation Oncology, Jiangxi Cancer Hospital, Nanchang, China (Y.Q.T.); Department of Radiation Oncology, Zhangzhou Affiliated Hospital of Fujian Medical University, Zhangzhou, China (W.L.C.); Department of Radiation Oncology, Quanzhou First Hospital Affiliated to Fujian Medical University, Quanzhou, China (B.A.S.); Department of Radiation Oncology, The First Affiliated Hospital of Fujian Medical University, Fuzhou, China (F.L.); Department of Radiation Oncology, Zhejiang Provincial Cancer Hospital, Key Laboratory of Radiation Oncology of Zhejiang Province, Hangzhou, China (C.J.T.); and Department of Radiation Oncology, Nanjing Medical University Affiliated Cancer Hospital, Jiangsu Cancer Hospital and Jiangsu Institute of Cancer Research, Nanjing, China (N.J.)
– sequence: 5
  givenname: Yi-Qiang
  orcidid: 0000-0002-2421-5298
  surname: Tang
  fullname: Tang, Yi-Qiang
  organization: From the Department of Radiation Oncology (L.L., G.Q.Z., J.Y.L., L.L.T., S.M.H., J.M., Y.S.) and Imaging Diagnosis and Interventional Center (C.M.X.), Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, 651 Dongfeng Rd East, Guangzhou 510060, China; Department of Computer Science and Engineering, The Chinese University of Hong Kong, Hong Kong SAR (Q.D., Y.M.J., P.A.H., H.C.); Imsight Medical Technology, Shenzhen, China (H.C.); Divisions of Radiation Oncology (J.T.S.W., M.L.K.C.) and Medical Sciences (M.L.K.C.), National Cancer Center Singapore, Singapore; Oncology Academic Programme, Duke-NUS Medical School, Singapore (M.L.K.C.); Department of Radiation Oncology, Jiangxi Cancer Hospital, Nanchang, China (Y.Q.T.); Department of Radiation Oncology, Zhangzhou Affiliated Hospital of Fujian Medical University, Zhangzhou, China (W.L.C.); Department of Radiation Oncology, Quanzhou First Hospital Affiliated to Fujian Medical University, Quanzhou, China (B.A.S.); Department of Radiation Oncology, The First Affiliated Hospital of Fujian Medical University, Fuzhou, China (F.L.); Department of Radiation Oncology, Zhejiang Provincial Cancer Hospital, Key Laboratory of Radiation Oncology of Zhejiang Province, Hangzhou, China (C.J.T.); and Department of Radiation Oncology, Nanjing Medical University Affiliated Cancer Hospital, Jiangsu Cancer Hospital and Jiangsu Institute of Cancer Research, Nanjing, China (N.J.)
– sequence: 6
  givenname: Wei-Lin
  surname: Chen
  fullname: Chen, Wei-Lin
  organization: From the Department of Radiation Oncology (L.L., G.Q.Z., J.Y.L., L.L.T., S.M.H., J.M., Y.S.) and Imaging Diagnosis and Interventional Center (C.M.X.), Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, 651 Dongfeng Rd East, Guangzhou 510060, China; Department of Computer Science and Engineering, The Chinese University of Hong Kong, Hong Kong SAR (Q.D., Y.M.J., P.A.H., H.C.); Imsight Medical Technology, Shenzhen, China (H.C.); Divisions of Radiation Oncology (J.T.S.W., M.L.K.C.) and Medical Sciences (M.L.K.C.), National Cancer Center Singapore, Singapore; Oncology Academic Programme, Duke-NUS Medical School, Singapore (M.L.K.C.); Department of Radiation Oncology, Jiangxi Cancer Hospital, Nanchang, China (Y.Q.T.); Department of Radiation Oncology, Zhangzhou Affiliated Hospital of Fujian Medical University, Zhangzhou, China (W.L.C.); Department of Radiation Oncology, Quanzhou First Hospital Affiliated to Fujian Medical University, Quanzhou, China (B.A.S.); Department of Radiation Oncology, The First Affiliated Hospital of Fujian Medical University, Fuzhou, China (F.L.); Department of Radiation Oncology, Zhejiang Provincial Cancer Hospital, Key Laboratory of Radiation Oncology of Zhejiang Province, Hangzhou, China (C.J.T.); and Department of Radiation Oncology, Nanjing Medical University Affiliated Cancer Hospital, Jiangsu Cancer Hospital and Jiangsu Institute of Cancer Research, Nanjing, China (N.J.)
– sequence: 7
  givenname: Bao-An
  orcidid: 0000-0003-1595-888X
  surname: Su
  fullname: Su, Bao-An
  organization: From the Department of Radiation Oncology (L.L., G.Q.Z., J.Y.L., L.L.T., S.M.H., J.M., Y.S.) and Imaging Diagnosis and Interventional Center (C.M.X.), Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, 651 Dongfeng Rd East, Guangzhou 510060, China; Department of Computer Science and Engineering, The Chinese University of Hong Kong, Hong Kong SAR (Q.D., Y.M.J., P.A.H., H.C.); Imsight Medical Technology, Shenzhen, China (H.C.); Divisions of Radiation Oncology (J.T.S.W., M.L.K.C.) and Medical Sciences (M.L.K.C.), National Cancer Center Singapore, Singapore; Oncology Academic Programme, Duke-NUS Medical School, Singapore (M.L.K.C.); Department of Radiation Oncology, Jiangxi Cancer Hospital, Nanchang, China (Y.Q.T.); Department of Radiation Oncology, Zhangzhou Affiliated Hospital of Fujian Medical University, Zhangzhou, China (W.L.C.); Department of Radiation Oncology, Quanzhou First Hospital Affiliated to Fujian Medical University, Quanzhou, China (B.A.S.); Department of Radiation Oncology, The First Affiliated Hospital of Fujian Medical University, Fuzhou, China (F.L.); Department of Radiation Oncology, Zhejiang Provincial Cancer Hospital, Key Laboratory of Radiation Oncology of Zhejiang Province, Hangzhou, China (C.J.T.); and Department of Radiation Oncology, Nanjing Medical University Affiliated Cancer Hospital, Jiangsu Cancer Hospital and Jiangsu Institute of Cancer Research, Nanjing, China (N.J.)
– sequence: 8
  givenname: Feng
  orcidid: 0000-0003-0167-9281
  surname: Liu
  fullname: Liu, Feng
  organization: From the Department of Radiation Oncology (L.L., G.Q.Z., J.Y.L., L.L.T., S.M.H., J.M., Y.S.) and Imaging Diagnosis and Interventional Center (C.M.X.), Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, 651 Dongfeng Rd East, Guangzhou 510060, China; Department of Computer Science and Engineering, The Chinese University of Hong Kong, Hong Kong SAR (Q.D., Y.M.J., P.A.H., H.C.); Imsight Medical Technology, Shenzhen, China (H.C.); Divisions of Radiation Oncology (J.T.S.W., M.L.K.C.) and Medical Sciences (M.L.K.C.), National Cancer Center Singapore, Singapore; Oncology Academic Programme, Duke-NUS Medical School, Singapore (M.L.K.C.); Department of Radiation Oncology, Jiangxi Cancer Hospital, Nanchang, China (Y.Q.T.); Department of Radiation Oncology, Zhangzhou Affiliated Hospital of Fujian Medical University, Zhangzhou, China (W.L.C.); Department of Radiation Oncology, Quanzhou First Hospital Affiliated to Fujian Medical University, Quanzhou, China (B.A.S.); Department of Radiation Oncology, The First Affiliated Hospital of Fujian Medical University, Fuzhou, China (F.L.); Department of Radiation Oncology, Zhejiang Provincial Cancer Hospital, Key Laboratory of Radiation Oncology of Zhejiang Province, Hangzhou, China (C.J.T.); and Department of Radiation Oncology, Nanjing Medical University Affiliated Cancer Hospital, Jiangsu Cancer Hospital and Jiangsu Institute of Cancer Research, Nanjing, China (N.J.)
– sequence: 9
  givenname: Chang-Juan
  orcidid: 0000-0002-8987-4542
  surname: Tao
  fullname: Tao, Chang-Juan
  organization: From the Department of Radiation Oncology (L.L., G.Q.Z., J.Y.L., L.L.T., S.M.H., J.M., Y.S.) and Imaging Diagnosis and Interventional Center (C.M.X.), Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, 651 Dongfeng Rd East, Guangzhou 510060, China; Department of Computer Science and Engineering, The Chinese University of Hong Kong, Hong Kong SAR (Q.D., Y.M.J., P.A.H., H.C.); Imsight Medical Technology, Shenzhen, China (H.C.); Divisions of Radiation Oncology (J.T.S.W., M.L.K.C.) and Medical Sciences (M.L.K.C.), National Cancer Center Singapore, Singapore; Oncology Academic Programme, Duke-NUS Medical School, Singapore (M.L.K.C.); Department of Radiation Oncology, Jiangxi Cancer Hospital, Nanchang, China (Y.Q.T.); Department of Radiation Oncology, Zhangzhou Affiliated Hospital of Fujian Medical University, Zhangzhou, China (W.L.C.); Department of Radiation Oncology, Quanzhou First Hospital Affiliated to Fujian Medical University, Quanzhou, China (B.A.S.); Department of Radiation Oncology, The First Affiliated Hospital of Fujian Medical University, Fuzhou, China (F.L.); Department of Radiation Oncology, Zhejiang Provincial Cancer Hospital, Key Laboratory of Radiation Oncology of Zhejiang Province, Hangzhou, China (C.J.T.); and Department of Radiation Oncology, Nanjing Medical University Affiliated Cancer Hospital, Jiangsu Cancer Hospital and Jiangsu Institute of Cancer Research, Nanjing, China (N.J.)
– sequence: 10
  givenname: Ning
  orcidid: 0000-0001-7697-5152
  surname: Jiang
  fullname: Jiang, Ning
  organization: From the Department of Radiation Oncology (L.L., G.Q.Z., J.Y.L., L.L.T., S.M.H., J.M., Y.S.) and Imaging Diagnosis and Interventional Center (C.M.X.), Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, 651 Dongfeng Rd East, Guangzhou 510060, China; Department of Computer Science and Engineering, The Chinese University of Hong Kong, Hong Kong SAR (Q.D., Y.M.J., P.A.H., H.C.); Imsight Medical Technology, Shenzhen, China (H.C.); Divisions of Radiation Oncology (J.T.S.W., M.L.K.C.) and Medical Sciences (M.L.K.C.), National Cancer Center Singapore, Singapore; Oncology Academic Programme, Duke-NUS Medical School, Singapore (M.L.K.C.); Department of Radiation Oncology, Jiangxi Cancer Hospital, Nanchang, China (Y.Q.T.); Department of Radiation Oncology, Zhangzhou Affiliated Hospital of Fujian Medical University, Zhangzhou, China (W.L.C.); Department of Radiation Oncology, Quanzhou First Hospital Affiliated to Fujian Medical University, Quanzhou, China (B.A.S.); Department of Radiation Oncology, The First Affiliated Hospital of Fujian Medical University, Fuzhou, China (F.L.); Department of Radiation Oncology, Zhejiang Provincial Cancer Hospital, Key Laboratory of Radiation Oncology of Zhejiang Province, Hangzhou, China (C.J.T.); and Department of Radiation Oncology, Nanjing Medical University Affiliated Cancer Hospital, Jiangsu Cancer Hospital and Jiangsu Institute of Cancer Research, Nanjing, China (N.J.)
– sequence: 11
  givenname: Jun-Yun
  orcidid: 0000-0002-4652-3881
  surname: Li
  fullname: Li, Jun-Yun
  organization: From the Department of Radiation Oncology (L.L., G.Q.Z., J.Y.L., L.L.T., S.M.H., J.M., Y.S.) and Imaging Diagnosis and Interventional Center (C.M.X.), Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, 651 Dongfeng Rd East, Guangzhou 510060, China; Department of Computer Science and Engineering, The Chinese University of Hong Kong, Hong Kong SAR (Q.D., Y.M.J., P.A.H., H.C.); Imsight Medical Technology, Shenzhen, China (H.C.); Divisions of Radiation Oncology (J.T.S.W., M.L.K.C.) and Medical Sciences (M.L.K.C.), National Cancer Center Singapore, Singapore; Oncology Academic Programme, Duke-NUS Medical School, Singapore (M.L.K.C.); Department of Radiation Oncology, Jiangxi Cancer Hospital, Nanchang, China (Y.Q.T.); Department of Radiation Oncology, Zhangzhou Affiliated Hospital of Fujian Medical University, Zhangzhou, China (W.L.C.); Department of Radiation Oncology, Quanzhou First Hospital Affiliated to Fujian Medical University, Quanzhou, China (B.A.S.); Department of Radiation Oncology, The First Affiliated Hospital of Fujian Medical University, Fuzhou, China (F.L.); Department of Radiation Oncology, Zhejiang Provincial Cancer Hospital, Key Laboratory of Radiation Oncology of Zhejiang Province, Hangzhou, China (C.J.T.); and Department of Radiation Oncology, Nanjing Medical University Affiliated Cancer Hospital, Jiangsu Cancer Hospital and Jiangsu Institute of Cancer Research, Nanjing, China (N.J.)
– sequence: 12
  givenname: Ling-Long
  orcidid: 0000-0002-8561-1454
  surname: Tang
  fullname: Tang, Ling-Long
  organization: From the Department of Radiation Oncology (L.L., G.Q.Z., J.Y.L., L.L.T., S.M.H., J.M., Y.S.) and Imaging Diagnosis and Interventional Center (C.M.X.), Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, 651 Dongfeng Rd East, Guangzhou 510060, China; Department of Computer Science and Engineering, The Chinese University of Hong Kong, Hong Kong SAR (Q.D., Y.M.J., P.A.H., H.C.); Imsight Medical Technology, Shenzhen, China (H.C.); Divisions of Radiation Oncology (J.T.S.W., M.L.K.C.) and Medical Sciences (M.L.K.C.), National Cancer Center Singapore, Singapore; Oncology Academic Programme, Duke-NUS Medical School, Singapore (M.L.K.C.); Department of Radiation Oncology, Jiangxi Cancer Hospital, Nanchang, China (Y.Q.T.); Department of Radiation Oncology, Zhangzhou Affiliated Hospital of Fujian Medical University, Zhangzhou, China (W.L.C.); Department of Radiation Oncology, Quanzhou First Hospital Affiliated to Fujian Medical University, Quanzhou, China (B.A.S.); Department of Radiation Oncology, The First Affiliated Hospital of Fujian Medical University, Fuzhou, China (F.L.); Department of Radiation Oncology, Zhejiang Provincial Cancer Hospital, Key Laboratory of Radiation Oncology of Zhejiang Province, Hangzhou, China (C.J.T.); and Department of Radiation Oncology, Nanjing Medical University Affiliated Cancer Hospital, Jiangsu Cancer Hospital and Jiangsu Institute of Cancer Research, Nanjing, China (N.J.)
– sequence: 13
  givenname: Chuan-Miao
  surname: Xie
  fullname: Xie, Chuan-Miao
  organization: From the Department of Radiation Oncology (L.L., G.Q.Z., J.Y.L., L.L.T., S.M.H., J.M., Y.S.) and Imaging Diagnosis and Interventional Center (C.M.X.), Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, 651 Dongfeng Rd East, Guangzhou 510060, China; Department of Computer Science and Engineering, The Chinese University of Hong Kong, Hong Kong SAR (Q.D., Y.M.J., P.A.H., H.C.); Imsight Medical Technology, Shenzhen, China (H.C.); Divisions of Radiation Oncology (J.T.S.W., M.L.K.C.) and Medical Sciences (M.L.K.C.), National Cancer Center Singapore, Singapore; Oncology Academic Programme, Duke-NUS Medical School, Singapore (M.L.K.C.); Department of Radiation Oncology, Jiangxi Cancer Hospital, Nanchang, China (Y.Q.T.); Department of Radiation Oncology, Zhangzhou Affiliated Hospital of Fujian Medical University, Zhangzhou, China (W.L.C.); Department of Radiation Oncology, Quanzhou First Hospital Affiliated to Fujian Medical University, Quanzhou, China (B.A.S.); Department of Radiation Oncology, The First Affiliated Hospital of Fujian Medical University, Fuzhou, China (F.L.); Department of Radiation Oncology, Zhejiang Provincial Cancer Hospital, Key Laboratory of Radiation Oncology of Zhejiang Province, Hangzhou, China (C.J.T.); and Department of Radiation Oncology, Nanjing Medical University Affiliated Cancer Hospital, Jiangsu Cancer Hospital and Jiangsu Institute of Cancer Research, Nanjing, China (N.J.)
– sequence: 14
  givenname: Shao-Min
  surname: Huang
  fullname: Huang, Shao-Min
  organization: From the Department of Radiation Oncology (L.L., G.Q.Z., J.Y.L., L.L.T., S.M.H., J.M., Y.S.) and Imaging Diagnosis and Interventional Center (C.M.X.), Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, 651 Dongfeng Rd East, Guangzhou 510060, China; Department of Computer Science and Engineering, The Chinese University of Hong Kong, Hong Kong SAR (Q.D., Y.M.J., P.A.H., H.C.); Imsight Medical Technology, Shenzhen, China (H.C.); Divisions of Radiation Oncology (J.T.S.W., M.L.K.C.) and Medical Sciences (M.L.K.C.), National Cancer Center Singapore, Singapore; Oncology Academic Programme, Duke-NUS Medical School, Singapore (M.L.K.C.); Department of Radiation Oncology, Jiangxi Cancer Hospital, Nanchang, China (Y.Q.T.); Department of Radiation Oncology, Zhangzhou Affiliated Hospital of Fujian Medical University, Zhangzhou, China (W.L.C.); Department of Radiation Oncology, Quanzhou First Hospital Affiliated to Fujian Medical University, Quanzhou, China (B.A.S.); Department of Radiation Oncology, The First Affiliated Hospital of Fujian Medical University, Fuzhou, China (F.L.); Department of Radiation Oncology, Zhejiang Provincial Cancer Hospital, Key Laboratory of Radiation Oncology of Zhejiang Province, Hangzhou, China (C.J.T.); and Department of Radiation Oncology, Nanjing Medical University Affiliated Cancer Hospital, Jiangsu Cancer Hospital and Jiangsu Institute of Cancer Research, Nanjing, China (N.J.)
– sequence: 15
  givenname: Jun
  orcidid: 0000-0002-1137-9349
  surname: Ma
  fullname: Ma, Jun
  organization: From the Department of Radiation Oncology (L.L., G.Q.Z., J.Y.L., L.L.T., S.M.H., J.M., Y.S.) and Imaging Diagnosis and Interventional Center (C.M.X.), Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, 651 Dongfeng Rd East, Guangzhou 510060, China; Department of Computer Science and Engineering, The Chinese University of Hong Kong, Hong Kong SAR (Q.D., Y.M.J., P.A.H., H.C.); Imsight Medical Technology, Shenzhen, China (H.C.); Divisions of Radiation Oncology (J.T.S.W., M.L.K.C.) and Medical Sciences (M.L.K.C.), National Cancer Center Singapore, Singapore; Oncology Academic Programme, Duke-NUS Medical School, Singapore (M.L.K.C.); Department of Radiation Oncology, Jiangxi Cancer Hospital, Nanchang, China (Y.Q.T.); Department of Radiation Oncology, Zhangzhou Affiliated Hospital of Fujian Medical University, Zhangzhou, China (W.L.C.); Department of Radiation Oncology, Quanzhou First Hospital Affiliated to Fujian Medical University, Quanzhou, China (B.A.S.); Department of Radiation Oncology, The First Affiliated Hospital of Fujian Medical University, Fuzhou, China (F.L.); Department of Radiation Oncology, Zhejiang Provincial Cancer Hospital, Key Laboratory of Radiation Oncology of Zhejiang Province, Hangzhou, China (C.J.T.); and Department of Radiation Oncology, Nanjing Medical University Affiliated Cancer Hospital, Jiangsu Cancer Hospital and Jiangsu Institute of Cancer Research, Nanjing, China (N.J.)
– sequence: 16
  givenname: Pheng-Ann
  orcidid: 0000-0003-3055-5034
  surname: Heng
  fullname: Heng, Pheng-Ann
  organization: From the Department of Radiation Oncology (L.L., G.Q.Z., J.Y.L., L.L.T., S.M.H., J.M., Y.S.) and Imaging Diagnosis and Interventional Center (C.M.X.), Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, 651 Dongfeng Rd East, Guangzhou 510060, China; Department of Computer Science and Engineering, The Chinese University of Hong Kong, Hong Kong SAR (Q.D., Y.M.J., P.A.H., H.C.); Imsight Medical Technology, Shenzhen, China (H.C.); Divisions of Radiation Oncology (J.T.S.W., M.L.K.C.) and Medical Sciences (M.L.K.C.), National Cancer Center Singapore, Singapore; Oncology Academic Programme, Duke-NUS Medical School, Singapore (M.L.K.C.); Department of Radiation Oncology, Jiangxi Cancer Hospital, Nanchang, China (Y.Q.T.); Department of Radiation Oncology, Zhangzhou Affiliated Hospital of Fujian Medical University, Zhangzhou, China (W.L.C.); Department of Radiation Oncology, Quanzhou First Hospital Affiliated to Fujian Medical University, Quanzhou, China (B.A.S.); Department of Radiation Oncology, The First Affiliated Hospital of Fujian Medical University, Fuzhou, China (F.L.); Department of Radiation Oncology, Zhejiang Provincial Cancer Hospital, Key Laboratory of Radiation Oncology of Zhejiang Province, Hangzhou, China (C.J.T.); and Department of Radiation Oncology, Nanjing Medical University Affiliated Cancer Hospital, Jiangsu Cancer Hospital and Jiangsu Institute of Cancer Research, Nanjing, China (N.J.)
– sequence: 17
  givenname: Joseph T S
  orcidid: 0000-0001-6123-1257
  surname: Wee
  fullname: Wee, Joseph T S
  organization: From the Department of Radiation Oncology (L.L., G.Q.Z., J.Y.L., L.L.T., S.M.H., J.M., Y.S.) and Imaging Diagnosis and Interventional Center (C.M.X.), Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, 651 Dongfeng Rd East, Guangzhou 510060, China; Department of Computer Science and Engineering, The Chinese University of Hong Kong, Hong Kong SAR (Q.D., Y.M.J., P.A.H., H.C.); Imsight Medical Technology, Shenzhen, China (H.C.); Divisions of Radiation Oncology (J.T.S.W., M.L.K.C.) and Medical Sciences (M.L.K.C.), National Cancer Center Singapore, Singapore; Oncology Academic Programme, Duke-NUS Medical School, Singapore (M.L.K.C.); Department of Radiation Oncology, Jiangxi Cancer Hospital, Nanchang, China (Y.Q.T.); Department of Radiation Oncology, Zhangzhou Affiliated Hospital of Fujian Medical University, Zhangzhou, China (W.L.C.); Department of Radiation Oncology, Quanzhou First Hospital Affiliated to Fujian Medical University, Quanzhou, China (B.A.S.); Department of Radiation Oncology, The First Affiliated Hospital of Fujian Medical University, Fuzhou, China (F.L.); Department of Radiation Oncology, Zhejiang Provincial Cancer Hospital, Key Laboratory of Radiation Oncology of Zhejiang Province, Hangzhou, China (C.J.T.); and Department of Radiation Oncology, Nanjing Medical University Affiliated Cancer Hospital, Jiangsu Cancer Hospital and Jiangsu Institute of Cancer Research, Nanjing, China (N.J.)
– sequence: 18
  givenname: Melvin L K
  orcidid: 0000-0002-1648-1473
  surname: Chua
  fullname: Chua, Melvin L K
  organization: From the Department of Radiation Oncology (L.L., G.Q.Z., J.Y.L., L.L.T., S.M.H., J.M., Y.S.) and Imaging Diagnosis and Interventional Center (C.M.X.), Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, 651 Dongfeng Rd East, Guangzhou 510060, China; Department of Computer Science and Engineering, The Chinese University of Hong Kong, Hong Kong SAR (Q.D., Y.M.J., P.A.H., H.C.); Imsight Medical Technology, Shenzhen, China (H.C.); Divisions of Radiation Oncology (J.T.S.W., M.L.K.C.) and Medical Sciences (M.L.K.C.), National Cancer Center Singapore, Singapore; Oncology Academic Programme, Duke-NUS Medical School, Singapore (M.L.K.C.); Department of Radiation Oncology, Jiangxi Cancer Hospital, Nanchang, China (Y.Q.T.); Department of Radiation Oncology, Zhangzhou Affiliated Hospital of Fujian Medical University, Zhangzhou, China (W.L.C.); Department of Radiation Oncology, Quanzhou First Hospital Affiliated to Fujian Medical University, Quanzhou, China (B.A.S.); Department of Radiation Oncology, The First Affiliated Hospital of Fujian Medical University, Fuzhou, China (F.L.); Department of Radiation Oncology, Zhejiang Provincial Cancer Hospital, Key Laboratory of Radiation Oncology of Zhejiang Province, Hangzhou, China (C.J.T.); and Department of Radiation Oncology, Nanjing Medical University Affiliated Cancer Hospital, Jiangsu Cancer Hospital and Jiangsu Institute of Cancer Research, Nanjing, China (N.J.)
– sequence: 19
  givenname: Hao
  orcidid: 0000-0002-8400-3780
  surname: Chen
  fullname: Chen, Hao
  organization: From the Department of Radiation Oncology (L.L., G.Q.Z., J.Y.L., L.L.T., S.M.H., J.M., Y.S.) and Imaging Diagnosis and Interventional Center (C.M.X.), Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, 651 Dongfeng Rd East, Guangzhou 510060, China; Department of Computer Science and Engineering, The Chinese University of Hong Kong, Hong Kong SAR (Q.D., Y.M.J., P.A.H., H.C.); Imsight Medical Technology, Shenzhen, China (H.C.); Divisions of Radiation Oncology (J.T.S.W., M.L.K.C.) and Medical Sciences (M.L.K.C.), National Cancer Center Singapore, Singapore; Oncology Academic Programme, Duke-NUS Medical School, Singapore (M.L.K.C.); Department of Radiation Oncology, Jiangxi Cancer Hospital, Nanchang, China (Y.Q.T.); Department of Radiation Oncology, Zhangzhou Affiliated Hospital of Fujian Medical University, Zhangzhou, China (W.L.C.); Department of Radiation Oncology, Quanzhou First Hospital Affiliated to Fujian Medical University, Quanzhou, China (B.A.S.); Department of Radiation Oncology, The First Affiliated Hospital of Fujian Medical University, Fuzhou, China (F.L.); Department of Radiation Oncology, Zhejiang Provincial Cancer Hospital, Key Laboratory of Radiation Oncology of Zhejiang Province, Hangzhou, China (C.J.T.); and Department of Radiation Oncology, Nanjing Medical University Affiliated Cancer Hospital, Jiangsu Cancer Hospital and Jiangsu Institute of Cancer Research, Nanjing, China (N.J.)
– sequence: 20
  givenname: Ying
  orcidid: 0000-0002-5888-2929
  surname: Sun
  fullname: Sun, Ying
  organization: From the Department of Radiation Oncology (L.L., G.Q.Z., J.Y.L., L.L.T., S.M.H., J.M., Y.S.) and Imaging Diagnosis and Interventional Center (C.M.X.), Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, 651 Dongfeng Rd East, Guangzhou 510060, China; Department of Computer Science and Engineering, The Chinese University of Hong Kong, Hong Kong SAR (Q.D., Y.M.J., P.A.H., H.C.); Imsight Medical Technology, Shenzhen, China (H.C.); Divisions of Radiation Oncology (J.T.S.W., M.L.K.C.) and Medical Sciences (M.L.K.C.), National Cancer Center Singapore, Singapore; Oncology Academic Programme, Duke-NUS Medical School, Singapore (M.L.K.C.); Department of Radiation Oncology, Jiangxi Cancer Hospital, Nanchang, China (Y.Q.T.); Department of Radiation Oncology, Zhangzhou Affiliated Hospital of Fujian Medical University, Zhangzhou, China (W.L.C.); Department of Radiation Oncology, Quanzhou First Hospital Affiliated to Fujian Medical University, Quanzhou, China (B.A.S.); Department of Radiation Oncology, The First Affiliated Hospital of Fujian Medical University, Fuzhou, China (F.L.); Department of Radiation Oncology, Zhejiang Provincial Cancer Hospital, Key Laboratory of Radiation Oncology of Zhejiang Province, Hangzhou, China (C.J.T.); and Department of Radiation Oncology, Nanjing Medical University Affiliated Cancer Hospital, Jiangsu Cancer Hospital and Jiangsu Institute of Cancer Research, Nanjing, China (N.J.)
BackLink https://www.ncbi.nlm.nih.gov/pubmed/30912722$$D View this record in MEDLINE/PubMed
BookMark eNpNkMtOwzAQRS1URB_wAWyQl2xSPE7sJMsqvCqVh1BhGznOpAQldrCTRf-eAEViFjNXmjNXujMnE2MNEnIObAkQJVdOlbVtlpxBCsnY-RGZgeBxACGIyT89JXPvPxiDSCTxCZmGLAUecz4j-hqxoxtUztRmRyvr6Grobat6LGlmTW8H972wFX12davcnm6HdqTebDO06Gmxpw8v65_DR-Vt9z4iZoeqoZlyujaj1Sk5rlTj8ewwF-T19mab3Qebp7t1ttoEOpRxHwjkhRwLmVQCMZKRBmApouZaVLKIKglhKWRZqIRplEoCasbisBJlFeuSL8jlr2_n7OeAvs_b2mtsGmXQDj7nkMZJGiVj9gW5OKBD0WKZd7_Z8r_H8C9cgWj9
CitedBy_id crossref_primary_10_1016_j_compmedimag_2024_102471
crossref_primary_10_1080_16878507_2020_1795565
crossref_primary_10_1007_s11604_023_01527_7
crossref_primary_10_1148_radiol_212526
crossref_primary_10_3389_fonc_2021_610804
crossref_primary_10_1002_cam4_4964
crossref_primary_10_1002_mp_15982
crossref_primary_10_1002_mp_16158
crossref_primary_10_1002_mp_14898
crossref_primary_10_2196_27122
crossref_primary_10_1038_s41597_024_03890_0
crossref_primary_10_1016_j_heliyon_2024_e30763
crossref_primary_10_1371_journal_pdig_0000755
crossref_primary_10_1016_j_meddos_2021_09_003
crossref_primary_10_3390_cancers16020383
crossref_primary_10_1109_RBME_2023_3269776
crossref_primary_10_1016_j_bone_2020_115561
crossref_primary_10_1088_1361_6560_acd29f
crossref_primary_10_1016_j_canrad_2021_08_020
crossref_primary_10_1007_s10143_022_01760_0
crossref_primary_10_1016_j_otc_2024_05_001
crossref_primary_10_1007_s00259_020_05125_x
crossref_primary_10_1007_s11427_021_2010_8
crossref_primary_10_1016_j_jpi_2023_100335
crossref_primary_10_1155_2022_1509490
crossref_primary_10_1007_s00371_023_02965_0
crossref_primary_10_1016_j_compmedimag_2025_102525
crossref_primary_10_1177_09731296241286282
crossref_primary_10_1016_j_ejrad_2023_111084
crossref_primary_10_3389_fonc_2019_00627
crossref_primary_10_1016_j_nanoen_2021_106783
crossref_primary_10_1002_jmrs_365
crossref_primary_10_1016_j_phro_2023_100426
crossref_primary_10_1109_TMI_2022_3144274
crossref_primary_10_1088_1361_6560_ad8e29
crossref_primary_10_1016_j_ijrobp_2024_11_096
crossref_primary_10_1109_TAI_2022_3187388
crossref_primary_10_1111_odi_70013
crossref_primary_10_1007_s11548_021_02326_z
crossref_primary_10_1016_j_radonc_2024_110367
crossref_primary_10_3390_cancers15010230
crossref_primary_10_1002_acm2_13440
crossref_primary_10_1016_j_radonc_2021_09_034
crossref_primary_10_1002_mp_17493
crossref_primary_10_1007_s00234_020_02513_w
crossref_primary_10_3389_fonc_2020_581347
crossref_primary_10_4103_digm_digm_25_22
crossref_primary_10_1002_acm2_13566
crossref_primary_10_1016_j_semcancer_2023_07_002
crossref_primary_10_3390_diagnostics11091523
crossref_primary_10_1007_s12553_024_00825_y
crossref_primary_10_1016_j_nanoen_2021_106526
crossref_primary_10_1002_osi2_1039
crossref_primary_10_1002_cam4_70188
crossref_primary_10_3348_kjr_2019_0847
crossref_primary_10_1007_s10489_021_02784_7
crossref_primary_10_1016_j_knosys_2023_110598
crossref_primary_10_3389_fonc_2022_998222
crossref_primary_10_3389_fvets_2023_1143986
crossref_primary_10_1007_s00405_023_08084_9
crossref_primary_10_1371_journal_pone_0240043
crossref_primary_10_3389_fonc_2022_945053
crossref_primary_10_1007_s00761_025_01773_6
crossref_primary_10_1007_s00234_025_03596_z
crossref_primary_10_1109_JBHI_2024_3372576
crossref_primary_10_1186_s13014_020_01617_0
crossref_primary_10_1002_mp_15146
crossref_primary_10_1016_j_biopha_2020_110255
crossref_primary_10_3389_fdgth_2025_1550407
crossref_primary_10_1007_s11912_025_01651_9
crossref_primary_10_1053_j_ro_2023_02_003
crossref_primary_10_1016_j_cmpb_2025_108965
crossref_primary_10_1002_mp_15936
crossref_primary_10_1155_abb_2610376
crossref_primary_10_3389_fonc_2020_01134
crossref_primary_10_3390_bioengineering11050504
crossref_primary_10_3390_diagnostics12061489
crossref_primary_10_2147_CMAR_S341583
crossref_primary_10_1186_s40644_022_00445_7
crossref_primary_10_1186_s13014_020_01562_y
crossref_primary_10_1088_2057_1976_ad6dcd
crossref_primary_10_1007_s00330_020_07558_2
crossref_primary_10_7759_cureus_50486
crossref_primary_10_1016_j_knosys_2021_108021
crossref_primary_10_1016_j_ctro_2021_10_003
crossref_primary_10_3389_fonc_2019_01192
crossref_primary_10_3389_fnhum_2022_1068713
crossref_primary_10_1002_jmri_27308
crossref_primary_10_1002_acm2_13470
crossref_primary_10_1007_s00330_020_07414_3
crossref_primary_10_1088_1361_6560_ac840f
crossref_primary_10_1016_j_ijrobp_2024_11_104
crossref_primary_10_1097_RLI_0000000000000600
crossref_primary_10_1016_j_asoc_2021_107722
crossref_primary_10_1016_j_tranon_2024_102245
crossref_primary_10_1016_j_isci_2024_110590
crossref_primary_10_1016_j_compbiomed_2024_108368
crossref_primary_10_1016_j_phro_2025_100790
crossref_primary_10_1002_mco2_32
crossref_primary_10_1016_j_diii_2020_03_006
crossref_primary_10_1016_j_ijrobp_2024_12_009
crossref_primary_10_1016_j_ijrobp_2020_10_005
crossref_primary_10_1016_j_ijrobp_2024_06_015
crossref_primary_10_1186_s13014_023_02221_8
crossref_primary_10_3389_fonc_2020_586145
crossref_primary_10_1016_j_ijrobp_2024_02_035
crossref_primary_10_1038_s41598_022_26771_1
crossref_primary_10_1259_bjr_20190209
crossref_primary_10_3390_cancers14061549
crossref_primary_10_1002_mp_13891
crossref_primary_10_1148_radiol_2019190385
crossref_primary_10_1002_cac2_12218
crossref_primary_10_3389_fonc_2021_785788
crossref_primary_10_3348_jksr_2020_81_3_467
crossref_primary_10_1002_cac2_12215
crossref_primary_10_3390_jcm12093077
crossref_primary_10_1002_acm2_13008
crossref_primary_10_1002_acm2_14461
crossref_primary_10_3389_fonc_2023_1301781
crossref_primary_10_1140_epjp_s13360_024_05660_8
crossref_primary_10_3389_fonc_2022_827991
crossref_primary_10_1016_j_nic_2020_08_003
crossref_primary_10_1038_s41598_021_02330_y
crossref_primary_10_1016_j_ejrad_2023_111264
crossref_primary_10_1080_0284186X_2021_1994645
crossref_primary_10_1088_1361_6560_ac0ea3
crossref_primary_10_1088_1361_6560_ac3345
crossref_primary_10_1016_S0140_6736_19_30956_0
crossref_primary_10_1002_cam4_4441
crossref_primary_10_1016_j_bspc_2020_102246
crossref_primary_10_1111_jcmm_18355
crossref_primary_10_1016_j_cmpb_2022_107266
crossref_primary_10_1016_j_landig_2025_03_001
crossref_primary_10_1162_dint_a_00204
crossref_primary_10_1038_s41598_020_74135_4
crossref_primary_10_1155_2021_2033806
crossref_primary_10_1186_s12880_022_00851_0
crossref_primary_10_1016_j_radonc_2023_109480
crossref_primary_10_3390_cancers14215221
crossref_primary_10_3389_fonc_2020_01572
crossref_primary_10_1016_j_neucom_2020_11_028
crossref_primary_10_1016_j_neucom_2021_08_118
crossref_primary_10_1088_2632_2153_ab869f
crossref_primary_10_1016_j_ijrobp_2022_03_031
crossref_primary_10_1007_s00259_023_06197_1
crossref_primary_10_3389_fonc_2024_1388297
crossref_primary_10_1016_j_media_2020_101954
crossref_primary_10_1177_00034894221095899
crossref_primary_10_1016_j_ccell_2023_12_020
crossref_primary_10_3389_fonc_2021_763114
crossref_primary_10_1002_acm2_14482
crossref_primary_10_1016_j_nic_2020_04_004
crossref_primary_10_1002_ima_22802
crossref_primary_10_1016_j_modpat_2025_100882
crossref_primary_10_1109_TMI_2024_3412923
crossref_primary_10_1080_1061186X_2024_2448711
crossref_primary_10_3389_fonc_2022_861857
crossref_primary_10_1016_j_ejmp_2021_05_010
crossref_primary_10_1016_j_inffus_2025_103586
crossref_primary_10_1016_j_radonc_2021_02_018
crossref_primary_10_1088_2516_1091_adc85e
crossref_primary_10_1007_s00500_020_04708_y
crossref_primary_10_1016_j_jdent_2023_104565
crossref_primary_10_1002_mrm_29450
crossref_primary_10_1002_acm2_13956
crossref_primary_10_1007_s13246_023_01229_4
crossref_primary_10_1016_j_radonc_2023_109574
crossref_primary_10_1093_toxsci_kfaa021
crossref_primary_10_1109_TCYB_2024_3390769
crossref_primary_10_4103_jcrt_jcrt_2006_24
crossref_primary_10_1016_j_media_2024_103447
crossref_primary_10_3390_cancers14235773
crossref_primary_10_7759_cureus_92964
crossref_primary_10_3389_fonc_2023_1190075
crossref_primary_10_3389_fmed_2023_1133269
crossref_primary_10_3390_s21237877
crossref_primary_10_1007_s00138_022_01314_w
crossref_primary_10_1002_uog_24843
crossref_primary_10_1155_2021_8280479
crossref_primary_10_1007_s13246_023_01327_3
crossref_primary_10_1016_j_cmpb_2022_106702
crossref_primary_10_1016_j_phro_2020_06_002
crossref_primary_10_3389_fonc_2021_764665
crossref_primary_10_3390_diagnostics13132159
crossref_primary_10_1016_j_media_2022_102381
crossref_primary_10_1038_s43018_021_00236_2
crossref_primary_10_1177_1533033820947484
crossref_primary_10_1016_j_ejca_2023_113504
crossref_primary_10_1016_j_compbiomed_2023_107356
crossref_primary_10_1016_j_arr_2025_102840
crossref_primary_10_1016_j_csbj_2021_05_023
crossref_primary_10_3389_fonc_2023_1177788
crossref_primary_10_1360_TB_2024_1304
crossref_primary_10_1016_j_jrras_2023_100775
crossref_primary_10_1093_bjr_tqad018
crossref_primary_10_3389_fonc_2025_1510568
crossref_primary_10_1016_j_intonc_2024_09_001
crossref_primary_10_1016_j_ejrad_2025_112407
crossref_primary_10_3389_fonc_2021_702270
crossref_primary_10_1088_1361_6560_abe553
crossref_primary_10_1038_s41467_022_33178_z
crossref_primary_10_1007_s10552_024_01942_9
crossref_primary_10_1038_s41746_023_00932_6
crossref_primary_10_1093_neuonc_noac192
crossref_primary_10_1002_nbm_4408
crossref_primary_10_1016_j_ijrobp_2024_11_064
crossref_primary_10_1002_cac2_12082
crossref_primary_10_1038_s41598_024_78424_0
crossref_primary_10_3389_fonc_2022_892171
crossref_primary_10_1038_s41597_025_05815_x
crossref_primary_10_1053_j_sult_2022_02_006
crossref_primary_10_1093_neuonc_noab071
crossref_primary_10_3171_2019_9_JNS191949
crossref_primary_10_1016_j_media_2020_101909
crossref_primary_10_1259_bjro_20230030
crossref_primary_10_1002_acm2_14296
crossref_primary_10_3389_fonc_2024_1377366
crossref_primary_10_3390_jcm12124005
crossref_primary_10_1016_j_oraloncology_2024_106796
crossref_primary_10_7759_cureus_91957
crossref_primary_10_3389_fendo_2024_1426781
crossref_primary_10_1007_s11547_023_01612_x
crossref_primary_10_3390_diagnostics12102478
crossref_primary_10_1007_s11604_021_01092_x
crossref_primary_10_1111_1754_9485_13286
crossref_primary_10_1016_j_eswa_2024_125208
crossref_primary_10_1155_2022_4073918
crossref_primary_10_1016_j_bbcan_2022_188681
crossref_primary_10_1016_j_phro_2025_100701
crossref_primary_10_1038_s41571_021_00524_x
ContentType Journal Article
DBID CGR
CUY
CVF
ECM
EIF
NPM
7X8
DOI 10.1148/radiol.2019182012
DatabaseName Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
MEDLINE - Academic
DatabaseTitle MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
MEDLINE - Academic
DatabaseTitleList MEDLINE
MEDLINE - Academic
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: 7X8
  name: MEDLINE - Academic
  url: https://search.proquest.com/medline
  sourceTypes: Aggregation Database
DeliveryMethod no_fulltext_linktorsrc
Discipline Medicine
EISSN 1527-1315
ExternalDocumentID 30912722
Genre Research Support, Non-U.S. Gov't
Journal Article
GroupedDBID ---
.55
.GJ
123
18M
1CY
1KJ
29P
2WC
34G
39C
4.4
53G
5RE
6NX
6PF
7FM
AAEJM
AAQQT
AAWTL
ABDPE
ABHFT
ABOCM
ACFQH
ACGFO
ACJAN
ACRZS
ADBBV
AENEX
AENYM
AFFNX
AFOSN
AJJEV
AJWWR
ALMA_UNASSIGNED_HOLDINGS
BAWUL
CGR
CS3
CUY
CVF
DIK
DU5
E3Z
EBS
ECM
EIF
EJD
F5P
F9R
GX1
H13
J5H
KO8
L7B
LMP
LSO
MJL
MV1
N4W
NPM
OK1
P2P
R.V
RKKAF
RXW
SJN
TAE
TR2
TRS
TWZ
VXZ
W8F
WH7
WOQ
X7M
YQI
YQJ
ZGI
ZKG
ZVN
ZXP
7X8
ID FETCH-LOGICAL-c367t-5e2b6666e06a5ee464c1109eec2c5f6b4f613d56dba80ce6a61ec0073f5df7cd2
IEDL.DBID 7X8
ISICitedReferencesCount 259
ISICitedReferencesURI http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000468618200020&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
ISSN 1527-1315
IngestDate Sat Sep 27 20:18:49 EDT 2025
Wed Feb 19 02:31:59 EST 2025
IsPeerReviewed true
IsScholarly true
Issue 3
Language English
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c367t-5e2b6666e06a5ee464c1109eec2c5f6b4f613d56dba80ce6a61ec0073f5df7cd2
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ORCID 0000-0002-2421-5298
0000-0002-8987-4542
0000-0003-1052-1566
0000-0003-1595-888X
0000-0001-7697-5152
0000-0003-0167-9281
0000-0002-8400-3780
0000-0002-4652-3881
0000-0002-1648-1473
0000-0002-7989-4224
0000-0002-3416-9950
0000-0002-8561-1454
0000-0003-3775-3877
0000-0003-3055-5034
0000-0002-5888-2929
0000-0002-1137-9349
0000-0001-6123-1257
PMID 30912722
PQID 2197894891
PQPubID 23479
ParticipantIDs proquest_miscellaneous_2197894891
pubmed_primary_30912722
PublicationCentury 2000
PublicationDate 2019-06-01
PublicationDateYYYYMMDD 2019-06-01
PublicationDate_xml – month: 06
  year: 2019
  text: 2019-06-01
  day: 01
PublicationDecade 2010
PublicationPlace United States
PublicationPlace_xml – name: United States
PublicationTitle Radiology
PublicationTitleAlternate Radiology
PublicationYear 2019
References 30917296 - Radiology. 2019 Jun;291(3):687-688
References_xml – reference: 30917296 - Radiology. 2019 Jun;291(3):687-688
SSID ssj0014587
Score 2.6715672
Snippet Background Nasopharyngeal carcinoma (NPC) may be cured with radiation therapy. Tumor proximity to critical structures demands accuracy in tumor delineation to...
SourceID proquest
pubmed
SourceType Aggregation Database
Index Database
StartPage 677
SubjectTerms Adolescent
Adult
Algorithms
Deep Learning
Female
Humans
Image Interpretation, Computer-Assisted - methods
Magnetic Resonance Imaging - methods
Male
Middle Aged
Nasopharyngeal Carcinoma - diagnostic imaging
Nasopharyngeal Neoplasms - diagnostic imaging
Nasopharynx - diagnostic imaging
Retrospective Studies
Young Adult
Title Deep Learning for Automated Contouring of Primary Tumor Volumes by MRI for Nasopharyngeal Carcinoma
URI https://www.ncbi.nlm.nih.gov/pubmed/30912722
https://www.proquest.com/docview/2197894891
Volume 291
WOSCitedRecordID wos000468618200020&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
hasFullText
inHoldings 1
isFullTextHit
isPrint
link http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1LSwMxEA5qRbz4ftQXEbwu7Waz2c1JSrUo2FKkSm8lj0npwd3ah-C_d7K7pSdB8LKnZNlNJjPf5EvmI-ROIUjF1CcJtOKYoIhYBhJSFUSaNTWkIddRcVH4Jen10uFQ9qsNt3l1rHLlEwtHbXPj98gbuLKSVPJUhvfTz8CrRnl2tZLQ2CS1CKGMt-pkuGYReFwI5Hnl1iCMwrhiNTEDaMyUneSeesB8xQdB9jvCLCJNZ_-_33hA9iqMSVulURySDciOyE63YtGPiXkAmNKqsuqYImylreUiR-wKlvpyVXlxd5HmjvbLYhR0sPzAVu-FK5tT_U27r89Fx57yOgjYJBsj5KRtL02U4atOyFvncdB-CiqxhcBEIlkEMTCNqYyAplAxABfc-GKkAIaZ2AnNHQZ-GwurVdo0IJQIwXiez8XWJcayU7KV5RmcE6qFk1w6GzpgXAubmmbiZCpdZEVoJNTJ7Wr4RmjMnqFQGeTL-Wg9gHVyVs7BaFr-6ChCZMMSxi7-0PuS7PqZLY90XZGaw6UM12TbfC0m89lNYSX47PW7PwDwyHs
linkProvider ProQuest
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Deep+Learning+for+Automated+Contouring+of+Primary+Tumor+Volumes+by+MRI+for+Nasopharyngeal+Carcinoma&rft.jtitle=Radiology&rft.au=Lin%2C+Li&rft.au=Dou%2C+Qi&rft.au=Jin%2C+Yue-Ming&rft.au=Zhou%2C+Guan-Qun&rft.date=2019-06-01&rft.eissn=1527-1315&rft.volume=291&rft.issue=3&rft.spage=677&rft_id=info:doi/10.1148%2Fradiol.2019182012&rft_id=info%3Apmid%2F30912722&rft_id=info%3Apmid%2F30912722&rft.externalDocID=30912722
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1527-1315&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1527-1315&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1527-1315&client=summon